miR-19b-3p promotes human pancreatic cancer Capan-2 cells proliferation by targeting phosphatase and tension homolog.
Pancreatic cancer
miR-19b-3p
phosphatase and tension homolog (PTEN)
proliferation
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
entrez:
19
7
2019
pubmed:
19
7
2019
medline:
19
7
2019
Statut:
ppublish
Résumé
Pancreatic cancer is a common cancer with a poor prognosis and an increasing morbidity. miR-19b-3p has been implicated in some cancers, however, its role in pancreatic cancer is unclear. Human pancreatic cancer cell line Capan-2 cells were transfected with miR-19b-3p mimic and inhibitor. Cell proliferation was measured by 5-Ethynyl-2'-deoxyuridine (EdU) staining assays. Cell cycle of Capan-2 cells was examined by flow cytometry. The expression of phosphatase and tension homolog (PTEN) was determined by real-time quantitative polymerase chain reaction (PCR) and western blotting analysis. Functional rescue experiments were performed through PTEN overexpression and miR-19b-3p mimic by using EdU staining assays. miR-19b-3p mimic significantly increased miR-19b-3p while miR-19b-3p inhibitor decreased that. EdU staining showed that miR-19b-3p overexpression promoted Capan-2 cells proliferation while miR-19b-3p inhibition decreased that. Flow cytometry analysis of cell cycle indicated that miR-19b-3p overexpression increased the percentage of Capan-2 cells in S phase while miR-19b-3p inhibition decreased that. Our study demonstrates that miR-19b-3p promotes Capan-2 cells proliferation by targeting
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic cancer is a common cancer with a poor prognosis and an increasing morbidity. miR-19b-3p has been implicated in some cancers, however, its role in pancreatic cancer is unclear.
METHODS
METHODS
Human pancreatic cancer cell line Capan-2 cells were transfected with miR-19b-3p mimic and inhibitor. Cell proliferation was measured by 5-Ethynyl-2'-deoxyuridine (EdU) staining assays. Cell cycle of Capan-2 cells was examined by flow cytometry. The expression of phosphatase and tension homolog (PTEN) was determined by real-time quantitative polymerase chain reaction (PCR) and western blotting analysis. Functional rescue experiments were performed through PTEN overexpression and miR-19b-3p mimic by using EdU staining assays.
RESULTS
RESULTS
miR-19b-3p mimic significantly increased miR-19b-3p while miR-19b-3p inhibitor decreased that. EdU staining showed that miR-19b-3p overexpression promoted Capan-2 cells proliferation while miR-19b-3p inhibition decreased that. Flow cytometry analysis of cell cycle indicated that miR-19b-3p overexpression increased the percentage of Capan-2 cells in S phase while miR-19b-3p inhibition decreased that.
CONCLUSIONS
CONCLUSIONS
Our study demonstrates that miR-19b-3p promotes Capan-2 cells proliferation by targeting
Identifiants
pubmed: 31317006
doi: 10.21037/atm.2019.04.61
pii: atm-07-11-236
pmc: PMC6603353
doi:
Types de publication
Journal Article
Langues
eng
Pagination
236Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Mol Cell Biochem. 2009 Nov;331(1-2):161-71
pubmed: 19437103
Nat Genet. 2011 Jun 05;43(7):673-8
pubmed: 21642990
FEBS Lett. 2011 Aug 19;585(16):2592-8
pubmed: 21781967
Blood. 2011 Nov 17;118(20):5487-97
pubmed: 21972292
Cancer Discov. 2011 Jul;1(2):158-69
pubmed: 21984975
Med Oncol. 2013 Dec;30(4):700
pubmed: 24026657
Adv Biol Regul. 2014 Sep;56:66-80
pubmed: 25088603
Lab Invest. 2015 Sep;95(9):1056-70
pubmed: 26098000
J Cancer. 2015 Oct 16;6(12):1230-5
pubmed: 26535064
Cell Rep. 2016 Feb 9;14(5):979-990
pubmed: 26804906
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
J Cell Mol Med. 2016 Jun;20(6):1191-7
pubmed: 27061862
Cancer Res. 2016 Jul 15;76(14):4149-59
pubmed: 27216198
Front Genet. 2016 Aug 31;7:143
pubmed: 27630665
Acta Biochim Biophys Sin (Shanghai). 2016 Dec;48(12):1085-1093
pubmed: 27797718
J Exp Clin Cancer Res. 2016 Dec 5;35(1):188
pubmed: 27919278
Eur J Gastroenterol Hepatol. 2017 Mar;29(3):e13-e18
pubmed: 28009716
JAMA. 2017 Jan 24;317(4):388-406
pubmed: 28118455
Am J Cancer Res. 2017 Jan 01;7(1):139-147
pubmed: 28123855
Cell Mol Life Sci. 2017 Aug;74(15):2783-2794
pubmed: 28289760
Nat Commun. 2017 May 12;8:15223
pubmed: 28497778
Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1225-1232
pubmed: 28619830
Cell. 2018 May 17;173(5):1191-1203.e12
pubmed: 29706542
J Sport Health Sci. 2017 Mar;6(1):125-126
pubmed: 30356527
J Sport Health Sci. 2017 Sep;6(3):292-294
pubmed: 30356613
J Sport Health Sci. 2018 Oct;7(4):433-441
pubmed: 30450252
Nat Commun. 2019 Jan 18;10(1):307
pubmed: 30659180
J Cell Physiol. 2019 Feb 14;:null
pubmed: 30767206